Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ)
CNY 28.56
(-1.52%)
CNY 28.56
(-1.52%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 397.93 Million | 1.19 Million | 246.88 Million | 303.95 Million | 185.7 Million | 99.54 Million |
| Net Income | 217.54 Million | 121.12 Million | 204.99 Million | 189.58 Million | 171.15 Million | 156.63 Million |
| Depreciation & Amortization | 87.3 Million | 65.25 Million | 55.48 Million | 45.72 Million | 39.78 Million | 41.82 Million |
| Deferred income taxes | -7.04 Million | 415.06 Thousand | 1.1 Million | 405.28 Thousand | 290.43 Thousand | -1.05 Million |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 66.23 Million | -169.95 Million | -19.12 Million | 67.71 Million | -29.54 Million | -104.72 Million |
| Other non-cash items | 16.92 Million | -15.22 Million | 5.53 Million | 933.55 Thousand | 4.3 Million | 5.8 Million |
| Investing Cash Flow | -352.16 Million | -487.25 Million | -290.07 Million | -202.58 Million | -100.64 Million | -79.85 Million |
| Investments in PPE | -328.85 Million | -327.37 Million | -240.82 Million | -189.19 Million | -77.79 Million | -84.51 Million |
| Acquisitions | -22.38 Million | 116.8 Thousand | 230.07 Thousand | 20.6 Million | 3.3 Million | 3270.00 |
| Investment purchases | -1 Million | -116.79 Thousand | -49.47 Million | -14 Million | -4.95 Million | - |
| Sales/Maturities of investments | - | 1.1 Million | -230.07 Thousand | -20.6 Million | -3.3 Million | - |
| Other Investing Activities | 73.39 Thousand | -160.99 Million | 230.07 Thousand | 605.27 Thousand | -17.89 Million | 4.65 Million |
| Financing Cash Flow | -88.18 Million | 447.9 Million | -96.17 Million | 65.52 Million | -40.33 Million | -98.33 Million |
| Debt repayment | -21.15 Million | -25 Million | -132 Million | -178 Million | -29 Million | -101 Million |
| Dividends payments | -45.36 Million | -45.36 Million | -40.5 Million | -35.68 Million | -32.53 Million | -57.33 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -1.42 Million | 530.58 Million | 77.64 Million | 279.2 Million | 21.2 Million | 59.99 Million |
| Accounts receivables | 88.2 Million | 33.52 Million | -2.72 Million | -15.57 Million | -61.71 Million | -82.37 Million |
| Accounts payables | 35.62 Million | -20.06 Million | 20.25 Million | -920.63 Thousand | 3.61 Million | 32.44 Million |
| Inventory | -50.56 Million | -183.83 Million | -37.75 Million | 83.8 Million | 28.26 Million | -53.74 Million |
| Other working capital | 20.86 Million | 415.06 Thousand | 1.1 Million | 405.28 Thousand | 290.43 Thousand | -50.98 Million |
| Cash at beginning of period | 293.85 Million | 332 Million | 471.37 Million | 304.47 Million | 259.75 Million | 338.41 Million |
| Cash at end of period | 251.44 Million | 293.85 Million | 332 Million | 471.37 Million | 304.47 Million | 259.75 Million |
| Capital Expenditure | -328.85 Million | -327.37 Million | -240.82 Million | -189.19 Million | -77.79 Million | -84.51 Million |
| Effect of forex changes on cash | - | 0.24 | 0.24 | 0.04 | 0.36 | - |
| Net cash flow / Change in cash | -42.4 Million | -38.15 Million | -139.36 Million | 166.89 Million | 44.72 Million | -78.65 Million |
| Free Cash Flow | 69.08 Million | -326.17 Million | 6.05 Million | 114.76 Million | 107.9 Million | 15.02 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 72.83 Million | 63.02 Million | 46.83 Million | 67.41 Million | 217.54 Million | 50.21 Million |
| Depreciation & Amortization | - | 28.25 Million | 28.25 Million | 26.69 Million | 87.3 Million | -34.45 Million |
| Deferred income taxes | - | - | - | - | -7.04 Million | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | 66.23 Million | -57.19 Million |
| Other non-cash items | -48.13 Million | 53.21 Million | -58.55 Million | 141.36 Million | 16.92 Million | 34.28 Million |
| Investing Cash Flow | -50.69 Million | -115.69 Million | -46.34 Million | -127.1 Million | -352.16 Million | -113.53 Million |
| Investments in PPE | -50.6 Million | -101.69 Million | -46.47 Million | -111.61 Million | -328.85 Million | -113.52 Million |
| Acquisitions | 10 Million | -10 Million | 126.84 Thousand | -15.54 Million | -22.38 Million | - |
| Investment purchases | - | -4 Million | - | - | -1 Million | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -92.97 Thousand | -4 Million | - | 7067.16 | - | -7067.16 |
| Financing Cash Flow | -23.39 Million | -3.41 Million | 142.93 Million | 4.86 Million | -88.18 Million | -43 Million |
| Debt repayment | -26.65 Million | -2.31 Million | -148.25 Million | -55.44 Million | -21.15 Million | -100 Million |
| Dividends payments | -49.84 Million | -5.41 Million | -5.11 Million | -45.36 Million | -45.36 Million | -4.41 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -207.9 Thousand | -5.2 Million | -207.9 Thousand | -484.65 Thousand | -1.42 Million | 61.41 Million |
| Accounts receivables | - | - | - | - | 88.2 Million | -129.07 Million |
| Accounts payables | - | - | - | - | 35.62 Million | - |
| Inventory | - | - | - | - | -50.56 Million | 71.88 Million |
| Other working capital | - | - | - | - | 20.86 Million | - |
| Cash at beginning of period | 305.19 Million | 337.16 Million | 251.47 Million | 192.23 Million | 293.85 Million | 355.92 Million |
| Cash at end of period | 255.8 Million | 305.64 Million | 336.34 Million | 251.44 Million | 251.44 Million | 192.23 Million |
| Capital Expenditure | -50.6 Million | -101.69 Million | -46.47 Million | -111.61 Million | -328.85 Million | -113.52 Million |
| Effect of forex changes on cash | - | - | - | - | - | -0.64 |
| Net cash flow / Change in cash | -49.38 Million | -31.52 Million | 84.86 Million | 59.2 Million | -42.4 Million | -163.68 Million |
| Free Cash Flow | -25.89 Million | -13.7 Million | -58.19 Million | 70.47 Million | 69.08 Million | -120.67 Million |
BLRX
IMCR
3025
GRCAF
ANLT
GMN